Which antibiotics can be safely co-administered with aztreonam?

Aztreonam Antibiotic Combinations

Aztreonam can be safely co-administered with clindamycin, gentamicin, tobramycin, cefazolin, ampicillin, vancomycin, and ceftazidime-avibactam, but is incompatible with nafcillin, cephradine, and metronidazole. 1

Compatible Antibiotics (FDA-Approved Stability Data)

The FDA label provides explicit compatibility data for aztreonam admixtures 1:

Stable for 48 hours at room temperature or 7 days refrigerated:

• Clindamycin phosphate
• Gentamicin sulfate
• Tobramycin sulfate
• Cefazolin sodium

These combinations maintain stability when prepared in normal saline (0.9% NaCl) or 5% dextrose at aztreonam concentrations ≤2% w/v.

Ampicillin sodium - Limited stability:

• In normal saline: 24 hours at room temperature, 48 hours refrigerated
• In 5% dextrose: Only 2 hours at room temperature, 8 hours refrigerated

Vancomycin hydrochloride and cloxacillin sodium:

• Stable for 24 hours at room temperature in peritoneal dialysis solution (Dianeal 137 with 4.25% dextrose)

Incompatible Antibiotics - DO NOT MIX

Aztreonam is physically incompatible with: 1

• Nafcillin sodium
• Cephradine
• Metronidazole

These combinations should never be prepared as admixtures. If sequential administration is required, flush the IV line thoroughly between drugs.

Clinically Important Combination Regimens

For Metallo-β-Lactamase (MBL)-Producing Organisms:

Ceftazidime-avibactam PLUS aztreonam is the preferred combination for infections caused by MBL-producing carbapenem-resistant Enterobacterales (CRE), including NDM and VIM producers 2. This combination demonstrates:

• Strong synergistic activity in vitro 3, 4, 5
• Significantly lower 30-day mortality (19.2% vs 44%) compared to alternative regimens 2
• 100% synergy rate against MBL-producing isolates 4

The mechanism: Ceftazidime-avibactam protects aztreonam from ESBL degradation, while aztreonam remains stable against MBLs that would otherwise inactivate ceftazidime.

For Febrile Neutropenia:

In high-risk patients with β-lactam allergies or when aminoglycosides must be avoided, aztreonam serves as an alternative to standard antipseudomonal β-lactams 6. It can be combined with:

• Vancomycin for Gram-positive coverage
• Fluoroquinolones (ciprofloxacin, levofloxacin) for enhanced Gram-negative activity

For Pseudomonas aeruginosa:

Aztreonam combinations show variable synergy 7:

• With aminoglycosides (gentamicin, tobramycin): 62% synergy rate 8
• With cefepime or ceftazidime: 75-85% partial or complete synergy 7
• With fluoroquinolones (especially gatifloxacin): 63-67% synergy 7

Critical Caveats

1. Pharmacokinetic interactions are minimal - small reductions in peak serum concentrations (9-13%) when combined with gentamicin or metronidazole have no clinical significance 9

2. Protein binding changes are negligible - maximum 5% variation when combined with nafcillin or cephradine 9

3. For combination therapy preparation: Always use separate IV lines or flush thoroughly between administrations when physical compatibility data is unavailable 1

4. Storage matters: Admixtures exceeding 2% w/v concentration should be used promptly unless prepared in sterile water or normal saline 1

5. Renal dosing: When combining aztreonam with aminoglycosides in patients with renal impairment, monitor renal function closely due to aminoglycoside nephrotoxicity risk 1